HOME
ABOUT US
STRATEGY
TEAM
PORTFOLIO
4BATLE ICAV
NEWSROOM
CONTACT
More
Takeda announces its intention to acquire TiGenix
Spark Therapeutics Announces Pricing and First-of-their-kind Patient Access Programs
4BIO Capital participates in $110M Series B Financing of Orchard Therapeutics
FDA Approves Spark Therapeutics’ LUXTURNA™ (voretigene neparvovec-rzyl)